Home / Transcripts / Pfizer Inc. (PFE) · November 3, 2026

Pfizer Inc. (PFE) Earnings Call Transcript & Summary

November 3, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 72 min

What were the key takeaways from Pfizer Inc.'s November 3, 2026 earnings call?

Pfizer Inc. reported a strong third quarter for 2026, with revenues of $16.6 billion, reflecting a 7% operational growth in non-COVID products. Adjusted diluted EPS was $0.87, exceeding expectations and prompting management to raise full-year revenue guidance by $1.5 billion to a range of $62 billion to $64 billion. The company also raised its adjusted EPS guidance to a range of $2.95 to $3.05, indicating confidence in its ongoing operational execution and pipeline advancements.

What topics did Pfizer Inc. cover?

What were Pfizer Inc.'s November 3, 2026 results?

Pfizer's strong performance in Q3 2026, characterized by robust revenue growth in non-COVID products and a positive outlook for its pipeline, supports a favorable investment thesis. However, the decline in COVID-19 product revenues and competitive pressures present risks that investors should monitor closely. Future catalysts include ongoing clinical trial results and potential regulatory approvals that could enhance the company's growth trajectory.

Earnings Call Speaker Segments

Francesca DeMartino executive
#1

Good morning, everyone, and welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. Thank you, on behalf of the Pfizer team, for joining us. You can access this call through audio webcast at pfizer.com. This morning, earlier in the day, we put out our third quarter 2026 results through a press release, and it's available on our website at pfizer.com. With me today are Dr. Albert Bourla, our Chairman and CEO; Cecile Guegan, our CFO; and Chris Boshoff, our scientific — our Chief Scientific Officer. Once they finish their prepared remarks, we'll open the line for questions. Our leadership team members will be standing by for the Q&A session. Before we begin, I'd like to remind everyone that we'll be making forward-looking statements and discussing certain non-GAAP financial measures. Please take a moment to read the disclaimers in our slide presentation, the press release issued this morning and the disclosures in our SEC filings, all of which you can find on the IR website at pfizer.com. Forward-looking statements made on this call carry substantial risks and uncertainty, speak only as of the call's original date, and we undertake no obligation to update or revise any of them. With that, I'll hand the call over to Albert.

Albert Bourla executive
#2

Thank you, Francesca. Good morning to all of you, and I appreciate you being on the call today. I'm happy to report yet another robust quarter at Pfizer; our outstanding commercial execution — which includes 32% operational revenue growth this quarter for our loans and acquired products — demonstrates the fundamental strength of our business. Strict financial management and continuous gains in productivity are generating efficiency and helping our margins in a positive way. And as our high-value R&D programs keep moving forward, we're confident we're on a path toward the next phase of substantial growth. Before I go on, I'd like to welcome Cecile Guegan as our Chief Financial Officer. Cecile comes to us with over 25 years of finance leadership experience and a demonstrated capacity to produce new sources of growth. During our global search, she distinguished herself through her expertise, her thorough understanding of Pfizer and our industry, and the strategic vision that I believe will assist Pfizer in unlocking lasting long-term value for patients and shareholders. I look forward to partnering with Cecile, and I'm confident he will help us execute with the discipline and ambition this next chapter < > requires. Now let me walk through a few highlights of our progress this quarter. As you're aware, during the past few years, we've committed nearly $80 billion to transactions that have given us key products now fueling commercial momentum as well as platforms holding transformative potential. Roughly 80% of that investment went toward Seagen, Metsera and Biohaven, and we're making solid headway in extracting maximum value from each. We're happy with how our acquired products have performed overall, growing 37% operationally this quarter. Our legacy Seagen portfolio rose 39% year-over-year in the U.S. during the quarter, powered by Padcev's strong showing; combining Seagen's medicines with the expanded reach of our commercial organization has strengthened our footprint in the oncology community. Physicians and care teams now have a wider range of options and greater expertise available to them, which helps patients and fuels growth for Pfizer. Seagen did more than bolster our commercial standing. It also broadened our capacity to uncover oncology breakthroughs, doubling our early-stage pipeline's size at the moment we completed the acquisition. Among our late-stage development programs, we're moving forward potential antibody drug conjugates that could deliver meaningful improvements for patients with cans. I'm pleased by how quickly things have progressed over the past year through our extensive clinical development program spanning our obesity portfolio; we intend to advance 10 active and planned Phase III trials in 2026, including one assessing a switch from approved weekly therapies to our investigational monthly GLP-1 peptide, berobenatide. We've achieved substantial progress with enrollment throughout our pivotal berobenatide program, and also our amylin combination program, where our Phase IIb study is now completely enrolled. We're aiming toward the first in a series of potential approvals for berobenatide in 2028, and planning for our go-to-market strategy is well underway. Biohaven has also been a strategically important addition for Pfizer. During the quarter, Nurtec posted 33% growth on an operational basis, fueled by underlying demand and superb commercial execution. We believe there is a genuine opportunity to support patients living with migraine, and for the oral CGRP class to serve as a major growth driver, even while we navigate market dynamics in a competitive landscape. We hold the leading position in the oral CGRP class within the U.S. and are striving to broaden that position globally. International growth is materializing as more patients are now able to access this treatment in key countries, among them the U.K., Italy and Japan. We are likewise heartened by robust uptake wherever we can broaden access. R&D execution in 2026 has been solid, and we keep prioritizing the highest value opportunities for patients and future growth throughout our four therapeutic focus areas. Our strong progress demonstrates the momentum behind our strategy. Over recent months, we secured two key regulatory decisions, one key pivotal readout and eight key pivotal study starts, together with compelling data we presented at several recent medical congresses. We are enthused about pipeline opportunities in areas of strategic focus and commercial strength. That spans late-stage programs across tumor types in oncology, among them multiple myeloma, breast cancer and lung cancer, within inflammation and immunology and, of course, in neococal vaccines. Chris will provide more detail on our recent advancement in various end months. Our pipeline strategy rests on disciplined prioritization and accelerated execution, and we are confident that we are moving forward our most significant opportunities for future patient impact and growth. Today, we are increasing our guidance for full year 2026 revenue and adjusted earnings per share. This mirrors our strong performance through the third quarter and confidence in our ability to execute our strategy, together with our financial discipline and the progress we keep making with our R&D pipeline; we believe Pfizer is well positioned to drive growth toward the end of the decade and create sustained value for patients and shareholders over the long term. We have deployed AI across our business with the aim of improving efficiency in manufacturing and serving how we engage physicians and patients. In R&D, we are working to speed innovation through faster target validation and better molecule and biomarker select. The recent launch of GENESIS, a new pharmacovigilance platform, demonstrates our commitment to harnessing advanced AI and intelligent automation for global safety monitoring. This typically involves a lengthy manual process for more than 600 products in over 120 countries. GENESIS takes on the administrative burden so our safety scientists can spend their time where it matters most, assessing causality, detecting safety signals and protecting patients; with that, I will turn it over to Cecile.

Cecile Guegan executive
#3

Thank you, Albert, and good morning. It's a privilege to address you today in my capacity as Pfizer's CFO. I look forward to carrying on my work with the executive leadership team and to guiding a finance organization of the highest caliber. I feel real enthusiasm about everything we can accomplish as a group, and I'll take on this position with financial discipline and a determination to convert Pfizer's scientific and commercial advances into lasting shareholder value. Our strategy has my full confidence, and I believe that together as a team we can produce durable long-term value for shareholders through rigorous capital allocation and disciplined execution. I'm pleased to now take you through the results for our third quarter, which reflect consistent commercial execution and financial discipline. Solid growth was achieved in revenues from our non-COVID products, while margin expansion was driven by product mix, productivity and cost management, which also made continued investment across our robust pipeline possible; with this year's performance, we have the confidence to raise our full year 2026 revenue guidance and to raise and narrow our adjusted diluted EPS guidance. Turning to the results: third quarter 2026 revenue of $16.6 billion came in above our expectations. We delivered strong 7% operational revenue growth for our non-COVID products, led by key brands in the U.S. and select international markets, and offset by lower revenues from our COVID-19 products. Turning to the bottom line, diluted EPS for the third quarter of 2026 came in at $0.56 as reported. Adjusted diluted EPS was $0.87, which exceeded what we had anticipated; that figure absorbs a $0.10 charge tied to the Innovent transaction. The better-than-expected result speaks to disciplined cost management and productivity gains throughout the company, achieved even as we put more money behind future growth drivers and moved a number of Phase III programs forward. Revenue contributions during the quarter were solid from adequate < >, the Venecal family, Nurtec and our brand, whereas our COVID-19 products and the Prevnar family saw declines in the quarter. Products we've launched or acquired brought in $3.8 billion of revenue during the quarter, expanding 32% on an operational basis, with the main contributors being Padcev, which rose $265 million, Nurtec, which added $135 million, and < >, up $114 million. We continue putting investment behind these products to offset LOE pressures anticipated in the coming years. Beyond that, results this quarter show unmistakable movement toward our goal of getting back to growth near the end of the decade. Staying disciplined on costs and continually optimizing throughout the company, including our manufacturing footprint, stay priorities. Our productivity efforts are yielding real progress, and we remain on schedule to realize almost all of the roughly $7.2 billion in net savings expected by the close of 2026 from ongoing cost improvement programs. Back in our prior quarterly update, we told you we were kicking off the next stage of these initiatives, which should generate roughly $2.5 billion more in net cost reductions between 2027 and 2029. Those savings bolster operating efficiency and give our margins a helpful lift. Meanwhile, we remain focused on putting money into pipeline programs we see as having the strongest shot at producing major breakthroughs for patients and building lasting value for shareholders. Adjusted gross margin for the third quarter reached 77%, largely on the strength of a favorable product mix and ongoing cost discipline. Breaking down the $6.8 billion adjusted operating expense figure: operational growth of 2% in adjusted SI&A came partly from a smaller favorable adjustment related to U.S. health care reform fees than the prior year, with that pressure partly offset by lower targeted marketing and promotion on growth drivers plus ongoing cost productivity savings. Adjusted R&D climbed 18% operationally, reflecting planned spending on priority oncology and obesity programs, among them several Phase III trial launches. Acquired in-process R&D dropped 52% operationally, mainly because this quarter carried a $650 million charge from the Innovent transaction while the comparable quarter last year had a $1.35 billion charge from the 3SBio transaction. For Q3 2026, adjusted operating margin came in at 36%, which shows we managed costs well, saw solid non-COVID revenue, and put more money into the business—though as I mentioned before, that figure was dampened by the AIPR&D charge related to the Innovent transaction. Adjusted diluted EPS for the quarter, as I noted earlier, was $0.87. With our performance so far this year—non-COVID products continuing to grow and disciplined execution—we're lifting our full-year 2026 revenue guidance by $1.5 billion at the midpoint, putting the range at $62 million to $64 million. We're restating our expectation of about $4 billion for the COVID products, with most ComeaNatio revenues anticipated in Q4, in line with the vaccination season. Accolade usage is still going to move with infection levels and demand for treatment. On top of that, our projection for R&D spending for the full year 2026 is now $10.8 billion to $11.8 billion. For the full year 2026, we're lifting and tightening adjusted diluted EPS guidance to $2.95 to $3.05. At the midpoint, that's a $0.10 increase, and it absorbs the $0.10 per-share effect of the Innovent transaction. Every other element of our financial guidance is being reaffirmed. This updated outlook shows our confidence in progress on non-COVID products through our cost improvement initiative, an anticipated full year adjusted gross margin in the mid-70s percent range, and ongoing investment in our priority pipeline programs. Now on capital allocation. Our priorities there haven't changed. We put money into the business at suitable returns, keep our investment-grade rating, increase the dividend, and return value to shareholders, all while keeping room for future moves that create value, share buybacks included. After the Innovent deal closed in Q3, we have roughly $6 billion of BB capacity at present. Across the first nine months of 2026, we directed $9.2 billion toward internal and external R&D and gave back $7.3 billion to shareholders via the quarterly dividend. Operating cash flow for Q3 year-to-date 2026 came to $8.8 billion, and leverage finished the quarter at 2.6x, a touch under our 2026 target of 2.7x. With the effect of what's coming up, we anticipate leverage staying near present levels or rising somewhat because of the — throughout the LOE transition window. Our attention stays on preserving a robust financial position while we keep funding innovation and backing returns to shareholders. To wrap up, I'd like to leave you with 2 main points: First, operational excellence. The non-COVID product kept delivering solid results, up 7% operationally, and our launched and acquired product rose 32% operationally, which offers further proof of our strong capabilities and steady execution. Second, financial discipline; we're boosting operating efficiency while allowing more pipeline investment in the program waiver that holds the greatest potential for patients and shareholders. All told, these results demonstrate that our strategy is being executed, that we are managing the forthcoming LOE transition, and that we are strengthening the foundation for a return to growth near the close of the digital. I'll now pass things to Chris.

Chris Boshoff executive
#4

Appreciate that, Cecile. Across each of our four therapeutic areas, the quarter brought meaningful progress. Let me walk you through a few of those programs in more detail. Starting with Elrexfio — our internally discovered BCMA bispecific — which has delivered two positive Phase III results in multiple myeloma patients exposed to two drug classes. In the most recent one, MM32, Elrexfio used alone demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus investigators' choice of three standard-of-care regimens already in use. The importance here is that those three standard-of-care choices provide a clear view of current treatment for CD38 refractory multiple myeloma in a population that continues to expand as anti-CD38 therapy moves into first-line use; and the results were impressive in their own right. In the interim analysis, more than 75% of Elrexfio patients remained free of disease progression or death from any cause, and the estimated 18-month progression-free survival rate was roughly 68%. In MM32, the safety profile for Elrexfio was consistent with what we already know, and it may also be differentiated: because infection prophylaxis measures were included from the start of MM32, rates of grade three or higher infections came in lower than those observed in MM5, Elrexfio's first positive pivotal trial in double-class exposed multiple myeloma. As context, those infection prophylaxis measures were not in place when MM5 began. They were implemented following early deaths from infections that were concentrated in China and two other countries during the COVID wave, which affected the overall hazard ratio of MM5. MM5 data are expected at a medical meeting before year-end and will give further information on efficacy and safety. All told, those encouraging Phase III data from MM32 and MM5 give us more confidence to advance Elrexfio into earlier lines of therapy. We're assembling a strong argument for fixed-dose Elrexfio as a monotherapy starting at first relapse, no matter what CD38 exposure came before. And since further pivotal trials in newly diagnosed myeloma are already running, Elrexfio's eligible patient population may expand roughly 5-fold, subject to clinical and regulatory success. Turning to atirmociclib, our possible first-in-class, highly selective CDK4 inhibitor — building on the leadership position we earned with IBRANCE — we're pushing atirmociclib forward as a potential next-generation backbone for first-line and early HR-positive breast cancer. Our KAT6 inhibitor, prifetrastat, is in development for later-line settings. Atirmociclib came out of our own discovery work, with the goal of doing better than CDK4/6 inhibitors—the backbone of today's standard of care for HR-positive breast cancer. The main drawback of this drug class involves safety and tolerability, and CDK6 inhibition plays a major part in causing adverse events. Our design for atirmociclib sought maximum efficacy by inhibiting CDK4 more strongly, while making the drug better tolerated by keeping CDK6 engagement to a minimum. When comparing CDK4 to CDK6, atirmociclib is 33x more selective, which stacks up well against the standard of care. Data from Year 2 have built enthusiasm for atirmociclib; on the left are our results presented at ESMO from the Phase II FOURLIGHT-1 trial, which tested atermaciclib combined with fulvestrant in patients who have HR-positive HER2-negative breast cancer. Every participant had already been treated with a CDK4/6 inhibitor; and it's worth noting that 92% of those on atirmociclib were randomized within 3 months of stopping a CDK4/6 inhibitor. Compared with investigators' choice of fulvestrant or everolimus plus exemestane, the atirmociclib regimen cut the risk of disease progression or death by 40%. These findings, in a population whose disease is highly refractory or resistant, boost our confidence in the ongoing Phase III trial of atirmociclib against investigators' choice of CDK4/6 inhibitor in the first-line setting. On the right, you'll see our data from the atirmociclib Phase II study in early breast cancer. When atirmociclib was given together with letrozole, 88% of participants' tumors demonstrated complete cell cycle arrest, compared with just 18% for letrozole on its own. Those findings support our plan to pair atirmociclib with giredestrant, a selective estrogen receptor degrader, in a Phase III trial in early breast cancer that we anticipate launching within the coming few months. The design of that study has been agreed with regulators, and it builds on the expected approval of giredestrant in this setting. This slide provides insight into safety and tolerability data as well as results from pivotal studies of the three approved CDK4/6 inhibitors combined with fulvestrant; note that these are cross-trial comparisons. That means we can't draw firm conclusions; even so, the data suggest that strong state selectivity produces better safety and tolerability, which allows for continuous dosing, very good adherence and possibly higher efficacy. Grade three or higher neutropenia was numerically less frequent with atirmociclib than with any approved agent, and no grade four neutropenia was reported. Any-grade diarrhea was lower with atirmociclib and similar to palbociclib and ribociclib. Dose reductions because of adverse events came in at 14% for atirmociclib versus 32% to 43% for the approved agents. Moving to tivunatamig, we're pushing forward a broad program for this PD-1 VGF bispecific antibody, which has best-in-class potential, with more than 1,200 patients treated worldwide and a consistent safety profile. We now have two Phase III studies underway, and two more Phase III studies should kick off during this year. The updated data presented at ESMO give us greater confidence as tivunatamig's development moves forward. In the ongoing Phase II study, the confirmed response rate for the pivotal dose of tivunatamig combined with doublet chemotherapy has climbed by about 20 percentage points since SITC 25 in both non-squamous and squamous first-line non-small cell lung cancer, and it now sits at roughly 80%, which is higher than what tislelizumab plus chemotherapy achieved in that same study. For both histologies, median progressive-free survival came in at close to 14 months, roughly 4 to 5 months better than the comparators. On the earnings call, we noted that tislelizumab's efficacy matched what earlier Phase III trials had shown for pembrolizumab, the top PD-1 antibody, which reinforces why the control arms are relevant. We're also encouraged by how tivunatamig's efficacy and safety results stacked up against Phase III data for ivonescimab, the PD-1 VGF bispecific antibody, though we keep in mind the limits of comparing across trials. Turning to I&I: tilrekimig, a possible first-in-class trispecific antibody, was designed in-house to hit several complementary drivers of type 2 inflammation at once — IL-4, IL-13 and TSLP. Phase II results in atopic dermatitis give us strong proof of concept. When given at the top monthly doses, tilrekimig yielded a response rate on EASI 75—meaning a 75% or better reduction on the Eczema Area and Severity Index—of about 50% after adjusting for placebo. Comparing across trials carries caveats, yet these Phase II results suggest the possibility of outperforming dupilumab, the biologic now considered the standard of care. In our ongoing Phase III program, the key secondary endpoints have been powered so this hypothesis can be tested head-to-head. On safety, tilrekimig showed a favorable profile at subcutaneous doses up to 400 milligrams given once every 4 weeks; the observed frequency of conjunctivitis and injection site reactions came in below the rates supported with dupilumab and were comparable to placebo. Beyond atopic dermatitis, tilrekimig is both a pipeline and a product opportunity, targeting pathways validated by approved therapies across nine different diseases, with late-stage studies underway in severe asthma and moderate-to-severe COPD. Turning to our potential best-in-class pneumococcal conjugate vaccine program, which builds on Prevnar's 25-plus year legacy of effectiveness and safety, we're advancing next-generation candidates designed for leading serotype and invasive disease coverage. For the pediatric indication, BCB 25 showed robust Phase II data: every one of the 20 serotypes that overlap with Prevnar 20 satisfied the meth-olose-4 IgG threshold that has traditionally served as the basis for noninferiority. Following Prevnar 20's pediatric approval in 2023, the FK introduced a revised and stricter noninferiority bar of 1.5-fold, which has been built into the design of our Phase III trial. Based on the Phase II findings and the narrower confidence intervals anticipated from a substantially larger Phase III sample, modeling indicates that at least 22 of the 25 serotypes in our pivotal study will clear this bar, when considered alongside sero response data, the functional OP test, and the totality-of-evidence approach to licensure. These findings leave us feeling assured as we work toward a best-in-class pediatric pneumococcal vaccine that guards against serotypes responsible for a combined estimated 84% of invasive disease cases among U.S. children younger than 5. That would amount to a gain of roughly 25 percentage points over Prevnar 20. Our Phase III effort is progressing well, and the Phase III lot-to-lot consistency study has already completed enrollment. On the adult side, PCB 35 takes the enhanced serotype three technology we confirmed with PCB 25 and applies it to additional key serotypes, and we anticipate launching a Phase I this year. Going forward, we foresee a robust rhythm of regulatory decisions, data readouts and pivotal study launches across the coming 12 months. Among these is data from MEVPRO-1, which, given how events are currently accruing, we now anticipate during Q1 of 2027. Should it pan out, MEVPRO-1 may underpin a regulatory green light for mevrometostat — the EZH2 inhibitor we discovered internally, a possible first-in-class agent for prostate cancer — broadening our franchise; having said that, I'll return the floor to Albert.

Albert Bourla executive
#5

Thank you, Chris. To wrap up, strong operational execution is fueling commercial momentum for our key growth brands. And I'd emphasize, notably with products we've launched and acquired. Our approach to capital allocation, meanwhile, is built to generate shareholder value over the long term. And the advances in our late-stage pipeline—with a substantial number of pivotal readouts anticipated in the near term—are bolstering our chance to broaden our leadership in key areas and improve outcomes for patients. I'm confident Pfizer is positioned well for growth as this decade draws to a close. And for creating shareholder value over the long term. We can see a clear path to our goal of a risk-adjusted high single-digit revenue CAGR from year-end 2008 through year-end 2033. Now let's turn to Q&A. Operator, please put the queue together.

Chris Schott analyst
#6

I’ve got two pipeline questions. Maybe first on the trispecific tilrekimig. How are you thinking about positioning this one in atopic derm as you consider, I guess, first-line versus second-line use — maybe just think about the very strong data you presented versus a very well-entrenched standard of care? And maybe just as a second part of that, can you just talk about the time lines for the indications beyond AD that you’re pursuing? The second question was then just pivoting over to the upcoming Phase I/IIa amylin and combo data that we’re going to see here — can you just help set some expectations about how you’re thinking about that data and then the type of titration schedule that’s being used in that study just to help us kind of frame out what we’re going to see with that readout.

Albert Bourla executive
#7

No. Thank you. Chris, would you like to cover the time lines of trispecific and, of course, the amylin and berobenatide questions. And then maybe Alexandre, you can speak a little bit about the commercial positioning.

Alexandre de Germay executive
#8

Thanks a lot for that question. So, as you're aware, we have now launched the Phase III program for recommend in atopic dermatitis II studies. Among those trials is a head-to-head study versus dupilumab, and we've also begun the Phase II/III study — a continuous design — for COPD, plus Phase III studies in severe asthma, with readouts expected in 2028 and 2029. Turning to amylin GLP-1, as you know, the SOLIS study has now fully enrolled — that's the robustly designed Phase IIb trial called amylin single agent and amylin plus and berobenatide, testing different doses and different titrations; we expect the efficacy readout from that trial in the second half of 2027. For the ongoing Phase I — Phase IIa study, we'll provide an update at the end of this year, bearing in mind that trial was designed for safety and PK clinical pharmacology, not for efficacy.

Albert Bourla executive
#9

And then what about the positioning of the trispecifics?

Executive executive
#10

Chris, appreciate those questions. I believe it's clear to everyone that this is an extremely large category. What our Sibinco and broader dermatology franchises have taught us is that many patient profiles need a different kind of therapy. We observe that quite clearly with the < > this is the map, and we see certain patients actually switching from one to the other, or dropping off. There's considerable circulation among those patients. We're building capabilities both in the U.S. and internationally, and we see that we're making solid progress. For example, as you saw this quarter, internationally we hit around $100 million combined across our two dermatology assets for the quarter. So we're beginning to have a nice base, and as I mentioned, once we move into the study's result, we'll be able to actually capture some of those lapsed patients as well as naive patients with a very specific profile that we're defining. So first-in-class, strong efficacy, and clearly an unmet medical need in the category.

Albert Bourla executive
#11

Thank you very much. Next question, please.

David Risinger analyst
#12

Yes. I'd like to congratulate Cecile on becoming Pfizer's new CFO, and I look forward to working together. My question concerns U.S. net price in the third quarter and beyond. Could you speak to any gross-to-net benefits to net sales during the third quarter, including from any 340B scrubbing, and discuss what U.S. net price prospects look like in the near term?

Cecile Guegan executive
#13

Thanks very much. First, I appreciate your good wishes. Regarding pricing in Q3, apart from the impact on adequate, which we had anticipated, we began in Q3 with the January price decrease. Honestly, I'd say our gross-to-net dynamics didn't shift in any really meaningful way in Q3. What we're seeing in terms of performance is largely the result of a robust market and volume, not from what's happening with the growth unit. Looking ahead, we aren't making any comments about 2027 today, but clearly our guidance for that year will take into account the various dynamics we're seeing—IRI, with two of our products launching in 2027, along with the effects of 340B changes, including a credit rebate model that begins in January, and also some of the MFN impacts we have following the agreement we have in this environment. In summary, though, the performance through Q3 really reflects strong execution rather than gross-to-net dynamics that won't persist.

Albert Bourla executive
#14

Very well. Thank you very much. next question, please.

Umer Raffat analyst
#15

Albert, it's clear there's been a lot of headway on SG&A improvements over the last couple of years, and I recognize that; it isn't a step function, but progress has happened. Still, I remember Dave saying before he moved on that most of the total net cost savings of $7.2 billion would be delivered by the end of '26. So looking again now at the Pfizer P&L, I see SGN R&D was roughly $24.5 billion back in 2022. In 2026 it's about the same as well. And I recognize R&D has risen somewhat, SG&A has come down somewhat. Still, the bigger forces shaping OpEx remain roughly within that $24 billion to $25 billion range. And I suppose, as you head toward dividend integrity, how are you viewing that cost lever going into the Padcev race?

Albert Bourla executive
#16

Cecile, would you like to answer this one?

Cecile Guegan executive
#17

Yes. So, as I said before, we remain on course to deliver the $7.2 billion in savings that we put in place under the first phase of our cost improvement programs. Those savings came from various areas: first, our manufacturing footprint for cost; second, R&D — but reinvested — and we are in fact boosting our R&D investment to support the pipeline products and programs we have, in addition to, obviously, the acquisition we made. And then on the SINA side, mostly arising from commercial and marketing expenses as well as SG&A. So that's what we're seeing today in our operating expenses. And I would then tie that to just the third quarter, which had some one-time dynamics that pushed SINA up; we still expect, based on guidance, to see a decline in SINA versus last year. So that's the first piece I would mention. Looking ahead, we have announced our second phase of the program with $2.5 billion of savings both in SG&A and in our case manufacturing; those will translate into savings. So we expect to see those translating and mitigating the margin erosion as part of the LOE transition in 2027 to 2029.

Akash Tewari analyst
#18

Just a few things. I recall that back in the spring you had roughly a 45 to 50 patient biomarker analysis on your stat sticks, and the plan was to decide whether to move from stage 1 into stage 2. Any news on that program? And really, how are you thinking about tork reduction and biomarker reduction relative to what we've seen from some of the degraders? Then on your GLP-1 amylin, I believe your Phase I/II just updated clinic trials to 201 patients — my understanding was it originally was planned to be nearer 400 — any color on what drove that call with the amylin GLP-1 combo with Metsera?

Albert Bourla executive
#19

Chris, both of those questions are for you.

Chris Boshoff executive
#20

All right, thank you so much. So starting with STAT6 — a potential first-in-class oral STAT6 program. Appreciate the question. This is a really important area for us, and for the I&I portfolio. As we said before, we've adjusted the program so that it includes some extra DDI studies. So a readout for STAT6 should come your way this year. Now on amylin and berobenatide: like I mentioned earlier, SOLIS-1 has completed enrollment, and that study < > wraps up at the end of next year. And the Phase I/IIa study was modified to accommodate the additional PK studies that we're running. But really there's nothing — no material changes to the trial.

Vamil Divan analyst
#21

Going back to the pipeline, we noticed that you registered a new Phase I study for your PIK3CA inhibitor on < > last week, and I heard what you said regarding atirmociclib and your KAT6. I'm wondering if you could explain how you see that asset fitting into your broader breast cancer strategy? My other question might come from ESMO — we saw the Volga, the AstraZeneca release, which perhaps implies less need for, or fewer cycles of, Padcev in bladder cancer patients. I'm curious whether you have any reactions to that data and what impact you'd outline — do you think the use of Padcev may play out in the future?

Albert Bourla executive
#22

Yes; so first, on the PLPK, we started a Phase I trial of a PIK3CA inhibitor that we discovered internally — a reminder that gedatolisib with salute is also a prize-discovered medicine. We have a clinical trial underway with relay involving the PIK3CA, alpha-pan, alpha-isoform selected inhibitor called, and the advanced also combined with atirmociclib. What's advantageous about atirmociclib is that we don't see DDIs, which has been experienced with all the other CDCs when combined with the PIK3CA. So that could be a pretty meaningful edge, as you were saying — as much as 40% of breast cancer — positive breast cancer, and up to 20%, 25% of two positive breast cancer will carry a PIK3CA mutation; so that's a key space for us. The second question concerned the bulker data. I'll just begin with a short answer. First, this strengthens the case for Padcev in massive invasive bladder cancer. It strengthens the case for Padcev together with the PD-1 in muscle-invasive bladder cancer. This further strengthens our conviction in the study — we've recently launched 309, which pairs Padcev with pembrolizumab in a bladder-sparing approach, along with the planned Phase III trial of Padcev plus tivunatamig that is also expected to begin later this year. Regarding the BARDA study, I'd like to note that it involved a population ineligible for cisplatin — pathological complete remission came in below what we've observed with pembro plus Padcev, which matters, and event-free survival was somewhat lower as well. And crucially, since this is a curative setting, it's still unclear which patients can be escalated. So that's an important question: who can actually receive less therapy?

Evan Seigerman analyst
#23

Now that you've taken over the capital allocation framework that our predecessor largely put in place, how are you thinking about the marginal dollars you're able to invest from here — across internal R&D, another bolt-on, the BD capacity you mentioned, deleveraging, and eventually restarting buybacks? Where do you see the highest prospective return for shareholders at the moment?

Cecile Guegan executive
#24

Our priorities are clear, and they aren't changing from what was already in place. I'd say they are — we have a solid plan to carry us through the LOE. So our priorities are impact for growth, maintaining our dividend over time, and then keeping a strong balance sheet. So during the LOE period, our operating cash flow, our financial assets, and access to capital markets will give us the ability to keep investing and maintain a dividend. Once we get past the LOE target, our operating cash flow grows along with the levers, and we have other options for continuing to increase shareholder value. And in that situation, share repurchases become, again, one of the levers we have in order to keep enhancing the shareholder return.

Albert Bourla executive
#25

Thank you very much, next question, please.

Steve Scala analyst
#26

I have two questions. First, with the pushout of MEVPRO-1, did anything change regarding the timelines for MEVPRO-2 and -3? That's my first question. My second one is for Cecile. You joined Pfizer while Warner-Lambert was being consolidated, and you've been through the Pharmacia, < > and Seagen acquisitions as well as many BD deals, including the one for Eliquis. One could argue that Pfizer's most successful products have come through deals. And in each of those years, just like now, Pfizer's pipeline was very good. So with that history in mind, why isn't another big deal Pfizer's primary focus? Or would you say the pipeline is significantly better now than at any point in the last 25 years?

Albert Bourla executive
#27

Good question. Cecile, what do you think?

Cecile Guegan executive
#28

Thank you; and that was a record — I joined with Wyeth, not Wires, so I don't have the history on all the deals; but I think Wyeth was one of the best acquisitions that we did, and I've seen since a transformation of Pfizer and strengthening definitely of our pipeline over the last 25 years. So what I would say is in terms of our priority, right? So we had, as Albert reiterated earlier, we have invested very significantly over the past few years in our key transaction and key acquisitions that are today are already kind of like driving success; we're talking about Padcev, we talked about MarTech, and we see a lot of opportunity that still remains in the pipeline, in Seagen, in Metsera. So where we have a lot to execute both commercially and on the RT side and on the commercial side; so really, as we look at — as we look at BD going forward and considering our capital allocation priorities, our focus is really on more bolt-on acquisitions that are going to complement the large and rich portfolio that we have in the four therapeutic areas that we are having; so looking at BD acquisition is obviously strategically aligned building upon our expertise and then obviously, providing the financial returns, appropriate return that we would be expecting.

Albert Bourla executive
#29

Thanks. Chris, could you say a bit about the MEVPRO timelines? And since there's so much interest in the product, maybe Aamir, you could also share a few thoughts on the potential.

Chris Boshoff executive
#30

Thanks a lot. I’ll keep this short. Since our previous discussion on the matter, the timelines for MEVPRO-1 and MEVPRO-2 have been revised—just to remind everyone, these are event-driven studies. That means timing reflects when we anticipate events will occur. So MEVPRO-1 will now read out in Q1 2027, and MEVPRO-2 in Q3 2027. And as you saw at ESMO, we have additional data, including a compelling 8.9 months PFS. Just to correct that: MEVPRO-2 is actually Q4 2027, per the update on clinicaltrials.com.

Albert Bourla executive
#31

And I think, you know, one is expected around February, if I remember right. Those are the current projections, based on how events are accruing at this point. And I mean, why are we so excited about MEVPRO when it comes to the commercial opportunity?

Aamir Malik executive
#32

I'd say there are probably three reasons we're enthusiastic. First, I'd remind everyone that our existing commercial presence is based in the U.S. with Astellas, but for us MEVPRO represents a fully worldwide opportunity, both in the U.S. and beyond; that's very significant and exciting. Second, as Chris noted, MEVPRO-2 and -3, across MEVPRO-1, -2 and -3, I believe we can potentially establish MEVPRO as a franchise spanning multiple indications; that gives us plenty of room to compete. And last, when we consider the total patient populations, we're discussing more than 50,000 in the U.S., nearly 50,000 in the EU in the U.K., another 14,000 in Japan, and 30% of that population might be addressable even with Metro I. So there's a substantial patient population, a worldwide opportunity, and clearly a space where we possess deep commercial expertise — those are the factors that make us excited about it.

Albert Bourla executive
#33

Thanks, Aamir. And it's easy to overlook that with XTANDI — one of our really large, robust products — we essentially hold half of the U.S. XTANDI business, and that's all. Here, we're going to have coverage across the entire United States, plus every international market worldwide.

Geoffrey Meacham analyst
#34

I have just a couple of things. First, Albert, on the broader policy picture: I know certainty is obviously difficult, especially after today. Still, when you look toward 2027, how do you see the potential risks stemming from MFN changes, or perhaps from greater scrutiny of the earlier OUS agreements? Then the second is for Chris regarding berobenatide. You have looked into — there are quite a few studies spanning the metabolic indications and going past obesity and diabetes, and I would like your view on growing berobenatide as a combination approach into inflammation, neuroscience, or even oncology, for instance. Clearly, the science around GLP-1 synergies is evolving rapidly here.

Albert Bourla executive
#35

Thanks, Geoff. Looking at policy, it clearly shapes our industry in a major way, and we're monitoring it closely. We're awaiting today's election results; but either way, it appears we'll end up with divided government. So I doubt much can advance on the legislative front, and I don't anticipate any MFN changes. The agreements, I believe, are signed and will remain in force through this government's term. And I expect Congress will show renewed interest in investigating several matters. But honestly, I don't expect policy to stay the same. It's a very big contract compared with what I told you a year ago. During 2025, tariffs and MFN both weighed on me heavily because of what each might set off. Getting through those challenges, in my view, delivered a stability that forecasts now show persisting, and that has restored investors' willingness to put money into our industry and sector. Having said that, I'll hand things over to Chris for his thoughts on GLP-1 and other topics.

Chris Boshoff executive
#36

Yeah, I'll jump in quickly. So initially, the aim is to establish berobenatide globally as a potentially best-in-class monthly subcutaneous GLP-1 for obesity. As you've seen, we're now starting additional studies in knee osteoarthritis and in obstructive sleep apnea, with or without PAP. We'll also announce further Phase III studies over the coming months. You're absolutely right about 2027 — we hope to announce some additional studies then, looking at the backbone of our portfolio, including Ignite, retention in oncology; you're right that this is an interesting area. And you'll also see acceleration of Phase I programs and current programs that are preclinically highly differentiated in this space. Thank you.

Albert Bourla executive
#37

All right. Let's take the next question.

Alexandria Hammond analyst
#38

I have two; so when you consider the Siwen Biosciences GLP-1 launch in China, how are the obesity and diabetes markets both performing up to now? And how does that influence your thinking about the commercial opportunity for berobenatide OUS? And then regarding the vaccine line, could you bring us up to date on the regulatory path ahead following the recent submission in Europe? How are your discussions with FDA coming along? And is there any meaningful difference between the FDA and EMA?

Albert Bourla executive
#39

I'm not certain I grasped the second question.

Executive executive
#40

Lyme disease and vaccines for Lyme.

Albert Bourla executive
#41

Right, so Alexandre — thanks a lot, Alex. Alexander, could you perhaps say a few words regarding our GLP-1 in China? And what are your expectations for it?

Alexandre de Germay executive
#42

Exactly right — and thanks for raising that. As you mentioned, Alex, we brought oblate to China at the end of April this year, and we're pleased with how things are going. The Egnoglutide launch in China is teaching us a great deal. What's becoming very clear is that within the broader chronic weight management space there are quite distinct patient segments — all of them meet the definition for product weight management, yet some come in with a more esthetic-driven purpose, seeking a very different product profile, and the way they obtain the product differs sharply from the other end of the spectrum: very heavy patients chasing considerably more efficacy and tolerability, which becomes a second fair point. So what we're clearly learning confirms our strategy — succeeding in Polypoint management requires a portfolio. A portfolio is also necessary because you must activate all of those distinct channels, and the expense of activating them gets amortized across that portfolio; these are very, very important confirmations of our strategy. Now, specifically on ecnoblotide: as you know, we recognized from the getgo that success in chronic weight management in China, in particular, demands two things. Naturally, we built a good profile — and ours is a very competitive one — but you also need type 2 diabetes, since it unlocks the hospital channel and, under local regulations, the e-commerce channels as well. I'm very happy to say that at the end of October we secured approval for our type 2 diabetes indication, which opens up that channel. Second, our competitors also have reimbursement access, and that matters greatly for competing effectively. So I'm also very glad to report that since June we cleared the — an RDL committees, and we now expect the final review by the end of this month. That way, hopefully, we can bring our product into the overall hospital reimbursement system. Together, those two things will truly mark the beginning of our market penetration.

Albert Bourla executive
#43

From where I sit, it's really interesting to observe how the commercial approach to obesity differs so much from anything else. For us, it actually brings back memories of when Viagra was launched, since there are many parallels. Consumers will spend their own money on products they see value in. Whether or not they get reimbursed doesn't matter, and that produces a dramatically different scale across international markets. The second point was that given the consumer character of these loans, e-commerce and the Internet didn't take off with Viagra — that was the first product essentially obtainable online, and it plays a key role. And naturally, we're already well positioned in that area, even more so than if we had already brought an obesity product to market, because our vaccines, our COVID product, and our migraine product all have substantial channel through Pfizer for all, which is our consumer — let's call it — web portal to the website. So I think it's — we're picking up a great deal right now in China, after having learned a great deal from our Viagra experience. And to add one more dimension, AI is transforming how promotions are carried out today, and not just at the physician level — actually, even more significantly, at the patient level. So we're learning a lot, and we're very pleased to be entering this market, because I think we — it's — it fits our capabilities. With that, I'll ask Chris to comment on the Lyme business.

Chris Boshoff executive
#44

Thanks for asking. As everyone is aware, cases of Lyme disease — and the burden that comes with it — are climbing worldwide. The EMA has validated the MAA for the Lyme disease vaccine candidate from Pfizer and Valneva, and with that validation, the CHMP will now start assessing the MAA, with an opinion on marketing authorization anticipated in 2027. We have also submitted a filing in Canada, and talks with the FDA are ongoing; we expect to share an update on that in Q4 of this year.

Albert Bourla executive
#45

Alexander, do you have anything to add here?

Alexandre de Germay executive
#46

Yeah. No, I really think this is a very exciting opportunity. Let me just remind you that we already operate an SME franchise in Europe, and we understand how to activate tickborne populations in those endemic areas, since we have a sales force and we have a commercial play with pharmacies. So we're very excited about this opportunity. The population's level of awareness is significantly higher than what we see in SME. So given that we've built these commercial muscles, once we get the approval, we're very much looking forward to the chance to commercialize this vaccine.

Albert Bourla executive
#47

And of course, awareness of this disease here in the U.S. is climbing very fast at the moment, since we are indeed seeing more severe cases and more incidents; so we're eager to wrap up our talks with FDA and get our filings submitted. Please, let's move on to the next question.

Analyst analyst
#48

Perhaps a couple of pipeline questions, quickly, for Chris. Regarding MEVPRO, you folks remain quite optimistic. I understand a formulation adjustment was made to reduce Cmax and boost tolerability. Could you perhaps weigh in on how you view dropouts and the formulation change in terms of driving your effect? Then on tilrekimig, your trispecific, again, something you're quite optimistic about. Could you just speak to neutralizing antibodies or ADAs, things that can be difficult with bispecifics and trispecifics, and how you feel about that?

Executive executive
#49

On the first question about protostat, as you noted, for the Phase III study we did adapt to a more tolerable dose with food, where we lowered the max yet observe an AUC similar to what we saw in Phase I; so we have strong confidence in the PK data and the dosing was chosen for the Phase III study. As for tilrekimig, we have not observed functional neutralizing antibodies or functional ADIs to date, and you are absolutely right that any bispecific or trispecific carries a long-term risk. But thus far, we haven't seen anything affecting efficacy. And in fact, longer-term follow-up from the studies we previously demonstrated shows us that we do not have an impact on efficacy. So, so far, so good.

Albert Bourla executive
#50

Very good. Let's keep it that way if you can please. Next question, please.

Asad Haider analyst
#51

Congratulations on the quarter, Cecile, and congratulations as well — best of luck to you. I have a couple of questions. First, on 2027: I appreciate the context you gave earlier regarding price dynamics, with respect to IRA and 340B, et cetera; but is there any additional high-level qualitative framing on other pushes and pulls next year that we should be aware of ahead of formal guidance? And how should we think about your guidance philosophy relative to Dave, broadly speaking? And then, looking out longer term, you are reiterating line of sight to high single-digit revenue CAGR towards the end of the decade off of a 2028 base, as well as siding operating leverage and margin expansion given the cost realignment initiatives. But consensus numbers are not really modeling that. There does seem to be a disconnect on both revenue and the earnings line versus your own expectations; so as you examine Street forecasts, what are the key assumptions that you think are getting most mismodeled in the P&L relative to your own internal expectations as you look out towards that period?

Albert Bourla executive
#52

Cecile, please make the comments on both.

Cecile Guegan executive
#53

Thanks, Asad, for the question and for the kind wishes as well. We'll be giving our 2027 guidance around the middle of December, the same way we did last year. So I'll just highlight the high-level key drivers we're seeing for 2027. First, obviously, is the LOE impact — not just in the U.S. with brand XTANDI and a few other products, but also internationally, where Eliquis is coming at the end of 2026. The other thing I'd mention is that, obviously, offsetting that is the ramp-up and launch of our — the ramp-up of our launch and acquired portfolio, which, again, as you've seen, is performing very strongly and offers a real opportunity for growth; and then obviously pricing, including MFN, which we will reflect in our guidance. And then our cost initiative program, which will let us keep investing toward the growth opportunity — or the growth driver that we have in the SINA marketing and commercial space — and then boost productivity and deliver savings, both on commercial spend and on general and administrative spend as well. So that sounded like the key trends for 2027; but again, more to come when we release guidance later on. As it relates to our high single digit growth aspiration versus the Street, if you look at where that difference comes from, it's not really coming from one place on one product. and so is our growth trajectory either. So what we see as a building block for our growth trajectory, obviously, one is the continued growth of our new and acquired products — not only because the market is still growing. Our penetration is still increasing. But on top of that, we're bringing new indications onto those products so we can keep addressing more patients and grow our presence in the market. The second thing is the pipeline; so while there are some obvious products making a key difference in our view versus a review obesity being one, some of the oncology products that you want, what I'll say is our growth trajectory doesn't rely on one single product or one single therapeutic area. We have a broad portfolio of products, several Phase III ongoing as well as our upcoming catalysts over the 18 to 24 months, which should give confidence to the outside world also to see the opportunity we have in bringing breakthrough to patients in significant areas of unmet need.

Albert Bourla executive
#54

Thank you, Cecile. Let me add this: as CEO, when I compare what we project internally against what the Street is forecasting, that naturally creates urgency for me to test our assumptions — to confirm whether we're right or wrong given the different views analysts hold. So we did exactly that, more than once. And our conclusion is what we've shared with you: we anticipate a high single digit, from 28% to 33%; and you're well aware of where the gaps sit among the products. As Cecile noted, those gaps aren't only in the pipeline, which a lot of analysts don't cover; so you have the situation where, out of 12, 13 analysts shaping the overall 2031 view, for certain products there are only five — they include this one, and the rest leave it out. So that's — this is what you'd expect with a pipeline. But we also observe quite large discrepancies on new products already launched, where the difference is very big. Let me cite just two examples where I believe people need to revisit their assessment. First, it concerns Norte, where we're already near $2 billion on this path, if you look at it, and — the Street has us at almost 2.5 by 2030. So I think a discrepancy exists there. I'll also give another example, Elrexfio, where for a competing product the Street forecasts $5 billion, and for us, $600 million; we're going to present a profile that is very similar in efficacy and better in tolerability and side effects. Now it remains to be proven. But I don't think $600 million versus $5 billion is justifiable, even with the information available today. So I think that as more data arrives on our pipeline and readouts, and as more data arrives on how the new products actually perform — that includes new launches and acquired products — I think the Street will probably begin adjusting their numbers, and there will be a conversion, a costly one. But with that, I think we've reached the end of our call, and I want to say that I'm very proud of our performance through the third quarter and of the execution. And my thanks go to my Pfizer colleagues. As I meet with our people — and I do so in our labs, at manufacturing sites, and in markets around the world — I see a team with tremendous talent, dedication, striving for breakthroughs that change patients' lives. We look forward to sharing further updates about our progress, and thank you for joining our call today, and thank you for your interest in Pfizer.

Operator operator
#55

Thanks. That brings today's meeting to a close. We appreciate the time and participation you've given us. You can disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Pfizer Inc. transcript - plus 131,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Pfizer Inc. earnings transcripts and 131,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.